Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 3, 2012, Pages 222-227

  Ang, Soo Fan ^a   Tan, Sze Huey ^a   Toh, Han Chong ^a   Poon, Donald Y H ^a   Ong, Simon Y K ^a   Foo, Kian Fong ^a   Choo, Su Pin ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

capecitabine; hepatocellular carcinoma; liver cancer; thalidomide

Indexed keywords

CAPECITABINE; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ACTIVITY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HEPATITIS B; HEPATITIS C; HUMAN; INSOMNIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 85027956130     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31820dbf56     Document Type: Review

References (29)

1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in adVanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390
2. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with adVanced hepatocellular carcinoma: a phase III randomized, double-blind,placebo-controlled trial. Lancet Oncol. 2009;10:25-34
3. Miller AA, Murry DJ, Owzar K, et al. Pharmacokinetic and phase I study of sorafenib for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2007;25:3538. (Abstract).
4. Abou-Alfa GK, Amadori D, Santoro A, et al. Is sorafenib (S) safe and effective in patients with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol. 2008;26:4518. (Abstract).
5. Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to adVanced stage liver cirrhosis. Oncologist. 2009;14:70-76
6. Wörns MA, Weinmann A, Pfingst K, et al. Safety and efficacy of sorafenib in patients with adVanced hepatocellular carcinoma inconsideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol. 2009;43:389-390
7. Torimura T, Sata M, Ueno T, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol. 1998;29:986-991
8. Theise ND. Macroregenerative (dysplastic) nodules and hepatocarcinogenesis: theoretical and clinical considerations. Semin Liver Dis. 1995;15:360-371
9. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91: 4082-4085
10. Kruse FE, Joussen AM, Rohrschneider K, et al. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor Graefes Arch Clin Exp Ophthalmol. 1998;236:461-466
11. Benjamin C, Robert L, Michael B, et al. Multi-centre phase II trial of thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncologica. 2007;46:234-238
12. Pinter M, Wichlas M, Schmid K, et al. Thalidomide in adVanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. Eur J Gastroenterol Hepatol. 2008;20:1012-1019
13. Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 2005;103:749-755
14. Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res. 1999;5: 1696-1702
15. Boige V, Raoul JL, Pignon JP, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with adVanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer. 2007; 97:862-867
16. Lee JO, Lee KW, Oh DY, et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol. 2009;20:1402-1407
17. Park SH, Lee Y, Han SH, et al. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer. 2006;6:3
18. Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for treatment of HCC, cholangiocarcinoma, and gallbladder carcinoma Cancer. 2004;101:578-586
19. Richard Quek A, Soon Thye L, Simon O, et al. Hepatocellular carcinoma-pathological complete response to oral capecitabine, megestrol and thalidomide. Acta Oncol. 2006;45:95-97
20. Jeong W, Chun HG, Cer D, et al. A combination of capecitabine and thalidomide in patients with hepatocellular carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement), 2006: 4142
21. National Cancer Institute. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Published, 2003-12-12
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216
23. CLIP Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program Investigators. Hepatology. 1998;28: 751-755
24. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for Hepatocellular Carcinoma and Comparison with the TNM Staging System, the Okuda Staging System, and the Cancer of the Liver Italian Program Staging System. Cancer. 2002;94:96
25. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338
26. Chiou HE, Wang TE, Wang YY, et al. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol. 2006;12:6955-6960
27. von Delius S, Lersch C, Mayr M, et al. Capecitabine for treatment of adVanced hepatocellular carcinoma. Hepatogastroenterology 2007;54:2310-2314
28. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992-2998
29. Hsu C, Yang T, Hsu C, et al. Modified-dose capecitabine+bevacizumab for the treatment of adVanced/metastatic hepatocellular carcinoma (HCC): a phase II, single-arm study. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Vol 25, No 18S 2007: 15190